18 Jun 2025
8m
BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.